Ecochlor is a company that specializes in environmental marine technology, specifically in the domain of ballast water treatment systems. The company offers a two-step treatment process for ballast water, which includes filtration and the use of chlorine dioxide, providing a solution that is not affected by changes in salinity, temperature, turbidity, or organics. The company primarily serves the maritime industry. It is based in Maynard, Massachusetts.
Latest Ecochlor News
Apr 6, 2023
Key companies profiled Ecochlor Inc., ALFA LAVAL, Evac, Auramarine Ltd., Veolia Water Technologies, Coldharbour Marine Ltd., GenSys GmbH, Damen Shipyards Group, Hyde Marine Inc., MH Systems Inc., NEI Treatment Systems, Optimarin AS Market dynamics Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. Customization purview If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. Drivers The impact of ballast water on the marine environment is a growing concern, and this has led to increased demand for BWTS systems that can effectively treat ballast water and reduce its impact on the environment. Besides this, growing public awareness of the impact of ballast water on the environment has increased demand for BWTS systems. The International Maritime Organization's (IMO) Ballast Water Management Convention (BWMC) requires ships to manage their ballast water to prevent the spread of invasive species. This regulation has led to increased demand for BWTS systems. Moreover, Governments across the globe are offering incentives and subsidies to ship owners who install BWTS systems, which has led to increased demand. The collaboration between the shipping industry, manufacturers, and regulatory bodies has led to the development of more effective BWTS systems, which has increased demand. Key Market Trends: The market for BWTS systems is seeing increasing consolidation as larger players acquire smaller companies, creating economies of scale and expanding their product portfolios. Hybrid BWTS systems that combine different technologies such as filtration, UV, and electro-chlorination are becoming increasingly popular as they offer a higher level of treatment and greater flexibility. Moreover, the use of UV-C technology for ballast water treatment is becoming more widespread due to its effectiveness in disinfecting water without the use of chemicals. Mobile BWTS systems that can be deployed on ships temporarily are becoming more common as they offer a solution for vessels that may only require treatment for a short period of time. With growing awareness of the impact of ballast water on the environment, there is a trend towards more sustainable BWTS systems that use less energy and produce fewer emissions. The use of digital technologies such as sensors and data analytics is becoming more common in BWTS systems, offering greater monitoring and control capabilities. Request Methodology & Get a Glimpse of Our Expertise: Restraints The cost of installing and maintaining BWTS systems can be high, which can deter some ship owners from investing in them. There is currently no global standard for BWTS systems, which can lead to confusion and uncertainty for ship owners and manufacturers. Developing effective and reliable BWTS systems that can operate in a marine environment can be challenging, and not all systems are able to meet the required standards. Competitive Landscape: Key companies in the market are focusing on supply chain management and good quality products to gain an edge over the competition. Also, the companies are focusing on various mergers and acquisitions to sustain a stable market share. For instance, South Korean company Techcross announced the acquisition of Norwegian provider Optimarin, a leading supplier of BWTS systems. This acquisition strengthened Techcross's position in the market and expanded its global reach. Evoqua Water Technologies announced the acquisition of ATG UV Technology, a UK-based provider of UV disinfection systems for the marine industry. This acquisition further expanded Evoqua's portfolio of BWTS systems, and strengthened the company's position in the market. Alfa Laval, a leading provider of marine equipment, launched an upgraded version of its PureBallast 2.0 BWTS system in 2021. The new system is designed to provide a higher level of treatment and can be installed on a wider range of vessels. Norwegian company Optimarin launched a new BWTS system called the OBS Cube in 2021. The system uses a combination of filtration and UV treatment to provide a high level of treatment and is designed for easy installation on a range of vessels. Moreover, companies are also putting emphasis on chemical-free ways of treating ballast water to lower the environmental impact. Key Segments of Ballast Water Treatment Systems Industry Research By Technology: What will be the estimated size of the Market in 2023? At what rate will the global Ballast Water Treatment Systems (BWTS) sales grow until 2033? Which are the factors hampering the Ballast Water Treatment Systems (BWTS) demand? Which region will spearhead the growth in the global industry by 2033? Which are the factors driving sales in the Ballast Water Treatment Systems (BWTS) Market during the forecast period? Check out more related studies published by Fact.MR Research: Mobile Water Treatment Systems Market Demand : The global mobile water treatment systems market demand is anticipated to grow at a CAGR of 8.9% to create an absolute $ opportunity of more than US$ 1,952.0 Mn during the forecast period (2020-2030). Solar Ventilation Systems Market Sales : Worldwide sales for solar ventilation systems to attain a market valuation of US$ 2.05 billion by 2032. Demand is projected to increase at a CAGR of 4.6%. Fire Alarm Systems Market Share : At present, the global fire alarm systems market share is valued at US$ 30.12 billion and is anticipated to reach US$ 57.08 billion by 2032. Worldwide demand for fire alarm systems is forecasted to increase at a CAGR of 6.6% between 2022 and 2032. Voice Evacuation Systems Market Size : The global voice evacuation system market size is estimated at USD 713.7 Million in 2022 and is forecast to surpass USD 1,636.1 Million by 2032, growing at a CAGR of 8.6% from 2022 to 2032. About Fact.MR We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction. Contact:
Ecochlor Frequently Asked Questions (FAQ)
Where is Ecochlor's headquarters?
Ecochlor's headquarters is located at 14 Nason Street, Maynard.
What is Ecochlor's latest funding round?
Ecochlor's latest funding round is Loan.
How much did Ecochlor raise?
Ecochlor raised a total of $8.42M.
Who are the investors of Ecochlor?
Investors of Ecochlor include Paycheck Protection Program and Hub Angels Investment Group.
Who are Ecochlor's competitors?
Competitors of Ecochlor include Vertos Medical, Cognoptix, Zipline Medical, OceanSaver, Aptus Endosystems and 7 more.
Compare Ecochlor to Competitors
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.
Vertos Medical operates as a medical device company. It focuses on developing minimally invasive treatments for lumbar spinal stenosis (LSS). Its technologies include Mild, which offers a guided therapeutic LSS treatment that requires no general anesthesia, no implants, and no stitches. The company was formerly known as X-Sten. It was founded in 2005 and is based in Aliso Viejo, California.
Ark Sciences LLC develops pharmaceutical products for animals and their pharmaceutical products are specifically engineered to provide the least invasive, non-surgical sterilization processes possible. Rather than castrating dogs, which can be painful and lead to possibly harmful side-effects, with Ark Sciences' patent protected products, veterinarians and animal welfare specialists have a safe, reliable and cost-effective sterilization treatment.
Gynesonics women's healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. It develops the sonata system for the transcervical treatment of symptomatic uterine fibroids under intrauterine sonography guidance. The sonata system uses radiofrequency energy to ablate fibroids under intrauterine sonography guidance. Gynesonics was founded in 2005 and is based in Redwood City, California.
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
DuoCure offers intraluminal minimally invasive implantable device for treatment of obesity.